PharmacyCodes



Diclonina [INN-Spanish] en es it fr

Diclonina [INN-Spanish] Brand names, Diclonina [INN-Spanish] Analogs

Diclonina [INN-Spanish] Brand Names Mixture

  • No information avaliable

Diclonina [INN-Spanish] Chemical_Formula

C22H26N2O2S

Diclonina [INN-Spanish] RX_link

http://www.rxlist.com/cgi/generic3/relpax.htm

Diclonina [INN-Spanish] fda sheet

Diclonina_[INN-Spanish] FDA

Diclonina [INN-Spanish] msds (material safety sheet)

Diclonina [INN-Spanish] Synthesis Reference

No information avaliable

Diclonina [INN-Spanish] Molecular Weight

382.52 g/mol

Diclonina [INN-Spanish] Melting Point

No information avaliable

Diclonina [INN-Spanish] H2O Solubility

Readily soluble as hydrobromide formulation

Diclonina [INN-Spanish] State

Solid

Diclonina [INN-Spanish] LogP

3.587

Diclonina [INN-Spanish] Dosage Forms

Tablet for oral administration (24.2 or 48.5 mg)

Diclonina [INN-Spanish] Indication

For the acute treatment of migraine with or without aura in adults.

Diclonina [INN-Spanish] Pharmacology

Eletriptan is a selective 5-hydroxytryptamine 1B/1D receptor agonist. In the anesthetized dog, eletriptan has been shown to reduce carotid arterial blood flow, with only a small increase in arterial blood pressure at high doses. While the effect on blood flow was selective for the carotid arterial bed, decreases in coronary artery diameter were observed. Eletriptan has also been shown to inhibit trigeminal nerve activity in the rat.

Diclonina [INN-Spanish] Absorption

Well absorbed after oral administration with a mean absolute bioavailability of approximately 50%.

Diclonina [INN-Spanish] side effects and Toxicity

Based on the pharmacology of the 5-HT1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.

Diclonina [INN-Spanish] Patient Information

No information avaliable

Diclonina [INN-Spanish] Organisms Affected

Humans and other mammals